HR+ HER2- Breast Cancer


Conference Reporter in HR+ HER2- Breast Cancer to Cover Key Topics Being Presented at the 2024 ASCO Annual Meeting

conference reporter by William J. Gradishar, MD, FACP; Sara M. Tolaney, MD, MPH

Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. Conference Reporter will feature community-selected experts and topics in HR+ HER2- Breast Cancer presented at this year’s ASCO Meeting.


  • Advances in the Treatment of HR2+/HER2- Breast Cancer
  • HR+/HER2- Breast Cancer and the Problem of Resistance to Endocrine Therapies
  • Identifying Candidates for Neoadjuvant or Adjuvant Anti-Her2 Therapy
  • Importance of Next-Generation Sequencing in Guiding Therapy Selection
  • Second-line Treatment for Advanced/Metastatic HR+/HER2- Breast Cancer
  • The Role of Predictive Biomarkers for Patients With HR+ Breast Cancer



This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Clinical Oncology.

William J. Gradishar, MD, FACP

    Chief of Hematology and Oncology
    Betsy Bramsen Professor of Breast Oncology
    Professor of Medicine
    Northwestern University Feinberg School of Medicine
    Chicago, IL

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Department of Medicine
Harvard Medical School
Boston, MA